Clinical Trial Update: ARQ 501 in Subjects With Cancer [Phase 1]

View source ↗

Summary

The Phase 1 trial of ARQ 501 in subjects with cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• ARQ 501

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Cancer | Phase 1 | Status: COMPLETED